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Abstract
Background: The study aims to assess the accuracy of multi-parametric prostate MRI (mpMRI) and 18F-choline
PET/CT in tumor segmentation for clinically significant prostate cancer. 18F-choline PET/CT and 3 T mpMRI were
performed in 10 prospective subjects prior to prostatectomy. All subjects had a single biopsy-confirmed focus of
Gleason ≥ 3+4 cancer. Two radiologists (readers 1 and 2) determined tumor boundaries based on in vivo mpMRI
sequences, with clinical and pathologic data available. 18F-choline PET data were co-registered to T2-weighted 3D
sequences and a semi-automatic segmentation routine was used to define tumor volumes. Registration of whole-
mount surgical pathology to in vivo imaging was conducted utilizing two ex vivo prostate specimen MRIs, followed
by gross sectioning of the specimens within a custom-made 3D-printed plastic mold. Overlap and similarity
coefficients of manual segmentations (seg1, seg2) and 18F-choline-based segmented lesions (seg3) were compared
to the pathologic reference standard.
Results: All segmentation methods greatly underestimated the true tumor volumes. Human readers (seg1, seg2)
and the PET-based segmentation (seg3) underestimated an average of 79, 80, and 58% of the tumor volumes,
respectively. Combining segmentation volumes (union of seg1, seg2, seg3 = seg4) decreased the mean
underestimated tumor volume to 42% of the true tumor volume. When using the combined segmentation with
5 mm contour expansion, the mean underestimated tumor volume was significantly reduced to 0.03 ± 0.05 mL (2.
04 ± 2.84%). Substantial safety margins up to 11–15 mm were needed to include all tumors when the initial
segmentation boundaries were drawn by human readers or the semi-automated 18F-choline segmentation tool.
Combining MR-based human segmentations with the metabolic information based on 18F-choline PET reduced the
necessary safety margin to a maximum of 9 mm to cover all tumors entirely.
Conclusions: To improve the outcome of focal therapies for significant prostate cancer, it is imperative to
recognize the full extent of the underestimation of tumor volumes by mpMRI. Combining metabolic information
from 18F-choline with MRI-based segmentation can improve tumor coverage. However, this approach requires
confirmation in further clinical studies.
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Background
The rationale for focal therapy of prostate cancer is based
on the concept of minimizing damage to off-target tissues
while achieving successful local treatment response. Focal
treatment methods include cryotherapy, laser ablation,
high-frequency focused ultrasound (HIFU), irreversible
electroporation, and focal brachytherapy [1–4]. The bene-
fit compared to radical treatment is reduced invasiveness
that lessens patient morbidity. The key to the success of
focal therapies is appropriate patient selection based on
an unequivocal, usually solitary, treatment target [5].
For focal therapies, it is imperative not only to accurately
differentiate significant from indolent prostate cancer [6, 7],
but also to precisely identify the tumor borders. In recent
years, multi-parametric prostate MRI (mpMRI) has
emerged as a useful tool for the detection and risk stratifi-
cation of primary prostate cancer and recently has been
incorporated into American Urological Association (AUA)
algorithms for patients with suspected or low-risk prostate
cancer [8–10]. When used optimally, mpMRI can cost-
effectively identify a significantly greater fraction of clinically
significant cancers (Gleason score ≥ 7 [≥ 3 + 4]) compared
to standard biopsy alone while minimizing the detection of
low-risk cancer [11–13]. These outcomes are important be-
cause accurate risk stratification of primary prostate cancer
historically has been fraught with overdiagnosis and over-
treatment [14–16]. However, mpMRI is not perfect. It suf-
fers from a large false-positive rate [17, 18], only moderate
inter-rater agreement [19], and a steep learning curve [20],
each resulting in unnecessary biopsies that drive complica-
tion rates and unwanted detection of low-risk disease.
It has recently been demonstrated that the addition of
positron emission tomography (PET) with 18F-choline to
mpMRI (PET/MRI) can significantly improve the
identification of Gleason ≥ 3+4 prostate cancer over
mpMRI alone [21], mainly by improving on the
comparatively low specificity of mpMRI [17]. The purpose
of this study was to determine the precision of tumor
boundary detection (segmentation) by visual inspection of
mpMRI and by semi-automatic segmentation based on
18F-choline PET in patients undergoing prostatectomy.
Due to prostate deformations, differing slice thicknesses
between imaging and histology, and differing spatial
orientation between imaging and whole-mount pathology,
registration of medical imaging to pathology from prosta-
tectomy specimen is challenging [22]. To overcome these
issues, we first accurately registered in vivo imaging to the
prostatectomy specimen using a multi-step approach pre-
sented in this paper.
Methods
Patient population
We report on a subset of patients within a Health
Insurance Portability and Accountability Act-compliant
registered prospective trial (Clinicaltrials.gov identifier:
NCT01751737) to assess the value of mpMRI and 18F-
choline PET prior to targeted and standard prostate
biopsies [21]. The institutional ethics committee approved
this protocol. Written informed consent was obtained.
Ten study subjects with rising PSA values and suspected
or known untreated localized adenocarcinoma of the
prostate recruited between November 2013 and June 2016
subsequently underwent prostatectomy following the
detection of Gleason ≥ 3+4 cancer at biopsy. The majority
of patients had additional low-grade (Gleason 3+3) can-
cers at final pathology (Table 1), but such low-grade dis-
ease was not the subject of this study.
The study participants, 65 ± 5 years of age (range 57–73),
had 1.2 ± 0.6 (range 0–2) biopsy procedures prior to enter-
ing the trial. Three subjects did not have a prior biopsy.
Previous biopsies resulted in four Gleason 3+3 cancers, one
Gleason 3+4 cancer, and no prostate cancer in the
remaining two cases. PSA levels at study entry ranged from
3.0 to 24.4 ng/mL (mean 8.65 ± 8.06).
Multi-parametric prostate MRI
All MR imaging was performed on the same 3 T unit
(Ingenia, Philips Healthcare, Andover, MA, USA) with-
out an endorectal coil using a 16-channel phased array
coil. Technical details are provided in the literature [21].
Briefly, the following in vivo MRI pelvic examinations
with and without contrast material were acquired prior
to biopsy: axial 3D T2-weighted (T2w) fast spin echo
(FSE) (voxel size 1.0 × 1.0 × 1.0 mm; repetition time
2051 ms; echo time (TE) 333 ms); axial/sagittal/coronal
T2w 2D FSE (voxel size 0.7 × 0.9 × 3.0 mm; repetition
time 4758 ms; TE 110 ms); axial diffusion-weighted im-
aging (voxel size 2.3 × 2.4 × 3.0 mm; b-factors 0, 100, and
800 s/mm2); and axial T1w pre- and dynamic post-
contrast 3D spoiled gradient echo with spectral adiabatic
inversion recovery fat saturation (dynamic contrast-
enhanced (DCE); in-plane voxel size 0.9 × 0.9 mm).
Patients were encouraged to empty their bladder prior
to scanning to minimize deformation effects on the
prostate. An apparent diffusion coefficient (ADC) map
was reconstructed for all diffusion-weighted imaging se-
quences, and subtraction imaging was generated for all
DCE sequences.
For ex vivo MRI, axial and coronal 3D T2w FSE (voxel
size 0.75 × 0.75 × 0.75 mm; repetition time 2451 ms; TE
320 ms) and axial diffusion-weighted imaging (voxel
size 0.5 × 0.5 × 3.0 mm; b-factors 0 and 800 s/mm2)
were acquired.
18F-choline PET/CT
18F-choline was synthesized as described in the literature
[23]. MRI and 18F-choline PET/CT were acquired
separately on average 21 days apart (range 0–47 days).
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18F-choline PET/CT scans were performed on a
Biograph TrueV mCT scanner with extended field of
view and a 40-channel helical CT (Siemens Medical
Solutions, Malvern, PA, USA) with an intrinsic axial
resolution of 4.1 mm FWHM and time-of-flight recon-
struction [24]. Twenty minutes after IV injection of
approximately 230 MBq of 18F-choline, a low-dose CT
transmission scan and a 10-min emission scan of the
lower abdomen and pelvis were performed. Images were
reconstructed using established methods [21].
Tumor segmentations
For segmentation of prostate cancer lesions, all mpMRI
series were reviewed on a PACS workstation (McKesson,
San Francisco, CA, USA). Two fellowship-trained expert
prostate MRI readers were tasked to contour the histo-
logically known significant prostate cancer on the T2w
sequence simulating a target volume definition for focal
prostate cancer treatment. For this purpose, the readers
had full knowledge of the prior reports of the in vivo
mpMRI scans as well as all histological reports of prior
biopsies, including targeted biopsies based on mpMRI
lesions identified. The readers were blinded to the seg-
mentation of the other reader as well as blinded to the
results from 18F-choline PET, the ex vivo specimen MRI
scans, and the final histology from prostatectomy. After
identification of a candidate lesion, an individual tumor
volume of interest (VOI) was defined based on the basis
of visual perception of the lesion borders on a MIM
Maestro (MIM Software, Cleveland, OH, USA) workstation
and assigned as seg1 (reader 1) and seg2 (reader 2) for
each case. A semiautomatic gradient-based segmentation
method (PETEdge, MIM Software, Cleveland, OH, USA)
without manual adjustments was used to determine the
borders of the MRI-identified lesions on 18F-choline PET
(assigned as seg3) [25]. Furthermore, all three
segmentation volumes of a given tumor were spatially
combined (union of seg1, seg2, seg3 = seg4) for further
analysis. Gradient edge detection identifies tumor on the
basis of a change in SUV at the tumor border. The
particular gradient method used calculates spatial
derivatives along tumor radii then defines the tumor edge
on the basis of derivative levels and continuity of the
tumor edge. This well-established method has been shown
in phantom studies to be more accurate and reproducible
compared to manual segmentation as well as threshold
methods determining the tumor border on the basis of a
percentage of the maximum activity within the tumor [26].
We also determined the accuracy of volume estimates
based on a commonly applied ellipsoid formula. For this
purpose, the maximum distance of the tumor in three
dimensions (transverse, coronal, sagittal) was determined
and the tumor volume was calculated based on the
ellipsoid formula (length × width × height × 0.52) [27].
This formula-based tumor volume estimate as well as all
other segmentations (seg1, seg2, seg3, seg4) were com-
pared to a true volumetric measurement obtained from
histology as depicted on high-resolution 3D T2w MRI as
standard of reference. Here, the tumor volume (in
milliliters) is defined by the sum of voxels encompassed
by the individually drawn tumor VOI. Accordingly, any
part of the standard of reference (histological) tumor
volume that was not included in the tumor volume esti-
mate (segmentation or formula-based) is defined as the
underestimated tumor volume.
Pathological evaluation
Whole-mount sections after prostatectomy were proc-
essed for routine histological assessment (hematoxylin/
eosin (HE) stain) using the paraffin embedding process
Table 1 Patient characteristics
Patient Age
(years)
PSA at time
of biopsy
(ng/mL)
Time interval
between MRI
and PET (days)
Time interval
between
imaging and
biopsy (days)
Time interval
from biopsy to
prostatectomy
(days)
Volume of
Gleason ≥ 7
disease at
pathology (mL)
Standard
biopsy
highest
Gleason
score
Targeted
biopsy
highest
Gleason
score
Final
maximum
Gleason
score at
prostatectomy
Number of
additional
Gleason 3+3
cancers at
prostatectomy
1 57 4.6 0 23 63 0.19 3 + 3 3 + 4 3 + 4 4
2 73 4.3 0 21 61 1.35 3 + 4 Negative 3 + 4 6
3 73 4.6 0 15 133 1.35 3 + 3 3 + 4 3 + 4 2
4 60 23.0 19 6 55 3.15 3 + 4 4 + 4 4 + 3 1
5** 64 3.0 0 14 120 0.15 3 + 3 3 + 3 3 + 4 4
6 65 24.4 25 56 99 1.37 Negative 3 + 4 4 + 3 0
7 62 4.6 47 28 146 0.57 Negative 4 + 3 4 + 3 2
8 66 20.4 45 49 106 6.31 3 + 4 4 + 3 4 + 3 0
9 59 4.7 37 35 169 0.91 3 + 3 4 + 5 4 + 5 0
10 66 8.6 35 7 79 3.73 Negative 3 + 4 3 + 4 0
**Excluded from analysis as lesion was not identified by readers
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and 3-μm sections. Each tumor focus was assigned a pri-
mary and secondary Gleason grade and staged according
to the American Joint Committee on Cancer guidelines
[28]. All tumor foci were microscopically assessed
whether any inhomogeneity of Gleason pattern within
Gleason ≥ 3+4 cancers was present. For this study, sig-
nificant prostate cancer was defined conservatively as
any Gleason ≥ 3+4 cancer regardless of the tumor
volume [29].
Registration process PET to MRI
First, PET data were registered onto 3D T2w MR using
commercially available software (MIM Maestro, Cleve-
land, Ohio, USA). The result of rigid registrations was
visually assessed using pelvic bones as landmarks. In se-
lected cases when rectal content or bladder filling shifted
the position of the prostate, a constrained intensity-
based, free-form deformable registration was added to
register the prostate on MRI and PET [30]. Such regis-
tration was possible using the outline of the bladder base
and internal prostatic structures (such as BPH nodules)
identified on both imaging as landmarks.
Registration process histology from prostatectomy to MRI
and PET
The second and more difficult registration step was the
mapping of histology onto MRI through the use of the
ex vivo prostate specimen MRI. Following prostatec-
tomy, an ex vivo T2w 3D specimen MRI was performed
with the prostate immersed in perfluorocarbon solution.
This solution was used to avoid susceptibility artifacts
(Fig. 1a) [21]. Using the specimen MRI data, the prostate
was segmented on a 3D workstation (Vitrea, Vital
Images, Minnetonka, MN, USA). The segmentation
served as the basis for a 3D-printed mold (Fig. 1b) that
could hold the prostate (Dimension Elite 3D, Stratasys,
Eden Prairie, MN, USA). The mold design included slits
spaced 3 mm apart that were later used to facilitate
accurate gross sectioning of the prostate specimen
within the mold (Fig. 1c). The specimen MRI also facili-
tated image registration utilizing intra-prostatic features
(e.g., BPH nodules).
Following complete fixation of the prostate, the prostate
borders at the base and apex were gross sectioned off the
specimen to allow detailed histological assessments for
potential extraprostatic extension. Then, a second MR
scan was performed with the prostate specimen posi-
tioned within the mold (Fig. 1d). Next, the prostate was
gross sectioned without repositioning (Fig. 1e), linking
corresponding histological whole-mount HE slides to their
respective sectioning planes from the second ex vivo MRI.
Since microtome sectioning for histology regularly de-
forms the HE slide relative to its representation on MR,
we obtained block-face photographs at the time of gross
sectioning (Fig. 2a). If notable deformation resulted from
sectioning, we utilized these block-face photographs to
register each deformed HE slide back to its original shape
at the time of gross sectioning.
Volumetric 3-mm stacks of HE whole-mount histology
sections (Fig. 2b) were then registered onto the ex vivo
high-resolution specimen MRI, providing a consistent
registration of the ex vivo MRI to pathology at 3-mm in-
tervals. The registration of whole-mount HE and ex vivo
HR MRI was rigid for the respective slice at the slit level.
However, in between those intermittent “rigid” registra-
tions, deformable registration was often required. Since
a given HE slice is repeated to cover a 3-mm-thick space
(in z-direction), deformable registration was needed to
follow contour and intraprostatic changes seen on MRI.
In essence, the prostate borders and well-identifiable
intraprostatic structures (urethra, BPH nodules, tissue
borders between peripheral and transitional zones) were
aligned using constrained intensity-based, free-form de-
formable registration.
All prostate cancer foci were outlined by the
pathologist on whole-mount HE slices (Fig. 2c), and
Fig. 1 Registration process step 1. Following prostatectomy, a 3D T2W MRI scan of the prostate specimen was performed (a), to accurately
segment the specimen for generating a mold design (b). After 3D printing, the specimen was placed into the mold (c), and a second high-resolution
3D T2W MR scan was performed (d). Then, the specimen was gross sectioned within the mold (e)
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lesion boundaries were transferred into the ex vivo MRI
(Fig. 2d/e). The registration quality was checked on
overlay images (Fig. 2f ), and the ex vivo T2w 3D MRI
with embedded histological information was registered
back into the in vivo T2w 3D MRI (Fig. 3).
Assessment of registration accuracy
We determined the accuracy of image registrations
between in vivo T2w MR and histology using well-
delineated BPH nodules as landmarks. One suitable BPH
nodule was identified in each of 10 prostatectomy cases.
First, the respective BPH nodules were segmented on
stacked HE histology slices. Since HE slices were not
continuous, but 3 mm apart, we used software
interpolation between each slice to fill the resulting gaps.
Then, the same BPH nodules were individually seg-
mented on ex vivo and in vivo MRI volumes (Fig. 3).
Common similarity coefficients were calculated to
determine registration accuracy: Hausdorff distance
(HD), mean distance to agreement (MDA), and Dice and
Jaccard [31]. Dice and Jaccard coefficients are similar
statistical measures of the spatial overlap between two
volumes as follows:
Dice A;Bð Þ ¼ 2 Aj ∩Bj
Aj j þ Bj j ; ð1Þ
Jaccard A;Bð Þ ¼ A∩Bjj
A∪Bj j ; ð2Þ
where A denotes the tumor volume estimate and B the
standard of truth (histological) tumor volume. Here, Dice
is defined as 2 × intersection volume/total sum of volumes,
while Jaccard describes the volume of intersection between
two volumes/volume of the union of these volumes. Both
overlap coefficients normalize the degree of intersection
from 0 (no overlap) to 1 (perfect overlap). The spatial dis-
tance coefficients HD and MDA describe the volumetric
maximum (HD) and mean distances (MDA) across all
points on a surface and their closest point on another sur-
face, where 0 mm reflects ideal outcome.
Statistics
Statistical analyses were performed using JMP 13 (SAS,
Cary, NC). Data were not normally distributed. To
compare contour measurements (seg1–3 vs. histological
Fig. 2 Registration process step 2. Individual sections of the specimen were photographed (a) and whole-mount sectioned for HE histology (b).
The tumor borders were marked by the pathologist (c). Stacked histology slices (d) were registered to the mold MRI scan (e). Registration
accuracy can be checked on overlay images (f)
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truth), a paired Wilcoxon signed-rank test was performed.
To compare similarity coefficients among readers (seg1,2)
vs. PET-based segmentation routine (seg3), an unpaired
Wilcoxon test was used. Data are presented as mean ±
standard deviation (SD), and P values less than 0.05 were
considered statistically significant.
Results
Patient characteristics are summarized in Table 1.
Histological tumor volumes were small with a median of
1.37 mL (range 0.15 to 6.31 mL). The Gleason ≥ 3+4
tumor with the lowest volume (case 5 in Table 1) was
not identified by both readers and excluded from further
analysis. The median time between mpMRI and PET,
and the median time between the second MRI scan and
the biopsy procedure were both 22 days. The median
time from biopsy to prostatectomy was 102 days (range
55–169 days). The histological results from standard
biopsies were upgraded on targeted biopsies in 8 of 10
cases. In one case, the targeted biopsy missed a Gleason
3+4 index cancer (case 2) identified on standard biopsy.
No significant intratumoral variations in Gleason pattern
within Gleason ≥ 3+4 cancers were observed.
Figure 3 demonstrates the accuracy of BPH nodule
registrations obtained from pathology, ex vivo MRI, and
in vivo MRI. Overall registration accuracy between in
vivo MRI and histology was excellent with maximum
HD below 2.7 mm and mean MDA below 0.5 mm with
limited inter-individual variability as indicated by their
respective standard deviations (Table 2). The overlap co-
efficients Dice and Jaccard were high between in vivo
MRI and final pathology. Note that the final registration
distance errors (in HD and MDA) between in vivo MRI
and histology were less than the sum of their respective
uncertainties for each registration step (Table 2).
The results of tumor border segmentations relative to
the histological reference standard are listed in Table 3.
Visual tumor border segmentation based on MRI and
PET-based thresholding substantially underestimated the
true tumor volumes (seg1 by 79%, seg2 by 80%, seg3 by
58%). As seen from Fig. 4, regardless of the segmenta-
tion method, the true tumor volume has no major
impact on the level of underestimation. Also, the under-
estimated tumor volume of the single high-risk (Gleason
4+5) cancer found (patient 9) is among the range of
otherwise intermediate risk cancers (Table 1). Imaging
Fig. 3 Determination of registration accuracy. Registered transaxial HE histology (a), specimen 3D T2W MRI (b), in vivo 3D 2TW MRI (c), ADC (d),
18F-choline PET (e), and fusion PET/MRI (f) are shown (SUV range 0–15). Contours of a BPH nodule obtained from histology (blue), ex vivo mold
MRI (yellow), and in vivo MRI (red) are displayed on corresponding slices. Also, contours of a Gleason 3+4 adenocarcinoma in the anterior gland
are shown on histology (a) and ex vivo corresponding specimen MRI (b)
Piert et al. EJNMMI Research  (2018) 8:23 Page 6 of 14
findings of a typical example case are shown in Fig. 5.
Similarity coefficients obtained from MRI and PET
contours reveal misplaced tumor borders compared to
histology (Table 3). Applying an ellipsoid formula to
estimate the VOI volume resulted in a significant
overestimation of the segmented volume by an average
48, 46, and 29% for seg1–3, respectively (p < 0.004 for
each) (Table 3).
When a 5-mm contour expansion was applied in all
directions from the tumor border segmentation edge, the
underestimated tumor volume decreased significantly
compared to the original segmentation (seg1: from 1.55 to
0.27 mL; seg2: from 1.82 to 0.57 mL; seg3: from 1.05 to 0.
15 mL, P < 0.001). However, due to variations in tumor
shape and lack of centering of the original segmentation,
minimum contour expansions of 15 mm (seg1–2) and
11 mm (seg3) would have been needed to fully cover all
Gleason ≥ 7 disease.
As indicated by Dice coefficients ≤ 0.41 and Jaccard ≤ 0.27,
agreement between human readers and human vs. PET-
based segmentations was low (Table 4). In fact, human
readers and PET-based segmentation often identified dif-
ferent regions of the histological tumor volume, which
lead to an improvement of the segmentation accuracy
when all segmentations were combined (seg4). The under-
estimated tumor volume of the combined segmentation
was significantly smaller than that of the individual human
readers (Table 3).
As expected, including a safety margin around the
segmentation volumes significantly decreased the under-
estimated tumor volume (Table 5). The combined seg-
mentation volume (seg4) with a 5-mm safety margin
covered the entire tumor volume in five of nine cases; in
the remaining four cases, a missed tumor volume of
0.03 ± 0.05 mL (2.04 ± 2.84% of the total tumor volume)
resulted (Fig. 5e–h). While the percent of the underesti-
mated volume was small, a contour expansion up to
9 mm was required to cover the entire tumor of irregu-
larly shaped lesions. In contrast, with even larger target
volumes at the 10-mm expansion level, complete tumor
coverage could not be achieved for all tumors in the study
by either human reader or the PET-based routine alone.
Discussion
The goal of focal prostate cancer therapies is to destroy
the entire tumor lesion using a non-invasive, well-
tolerated treatment. Such a treatment would preserve
normal genitourinary function while providing sufficient
therapeutic efficacy. In order to be effective, focal pros-
tate cancer therapies require accurate localization of the
disease. The high anatomic detail provided by mpMRI at
3 T appears well suited to provide necessary guidance.
However, it has already been recognized that lesion ex-
tension is typically underestimated by mpMRI [32].
Therefore, all focal treatment approaches are performed
with a safety margin [33]. The key question is how to
optimally define such safety margins.
We developed and applied a methodology for objective
retrospective registration of whole-mount pathology to
in vivo MRI and PET imaging. This method enabled us
to determine whether in vivo imaging correctly identi-
fied and classified all tumor lesions found at final
pathology from prostatectomy specimen [21]. A similar
approach was used to determine boundary errors based
on visual image inspection on MRI as well as mathemat-
ical thresholding techniques on 11C-choline PET [34].
To our knowledge, this is the first report on the
accuracy of prostate cancer segmentations from mpMRI
and 18F-choline PET using registered whole-mount hist-
ology as the reference standard. For this performance test,
we simulated the clinical situation of a radiologist tasked
to delineate tumor borders prior to a hypothetical planned
ablation, in which readers were aware of the interpretation
of the mpMRI and biopsy-based histology but had no
knowledge of the 18F-choline PET results, ex vivo MRIs,
or the pathology from the prostatectomy specimen.
Determining the accuracy of prostate cancer segmen-
tation in MRI is difficult. Typically, error metrics are de-
rived from measured inter-observer variability [35]. This
is subject to bias because it lacks a reference standard.
We took a different approach by registering imaging to
histology, thereby enabling error measurements of
tumor border delineation. Our results indicated a sub-
stantial difference between “perceived” (i.e., by imaging)
and “true” (i.e., by histology) tumor borders. Human
Table 2 Accuracy of BPH nodule registration across mpMRI and histology
N = 10 Volume (in mL) HD (in mm) MDA (in mm) Dice Jaccard
Histology vs. ex vivo T2w MRI 2.84 ± 3.56
[0.85; 0.15–10.23]
1.64 ± 0.51
[1.47; 0.9–2.5]
0.28 ± 0.09
[0.29; 0.14–0.41]
0.90 ± 0.04
[0.91; 0.81–0.96]
0.83 ± 0.07
[0.83; 0.68–0.93]
Ex vivo T2w MRI vs. in vivo T2w MRI 2.99 ± 3.72
[0.96; 0.2–11.01]
2.27 ± 0.71
[2.03; 1.66–3.99]
0.41 ± 0.12
[0.42; 0.21–0.63]
0.86 ± 0.07
[0.85; 0.76–0.97]
0.76 ± 0.11
[0.74; 0.62–0.94]
In vivo T2w MRI vs. histology 3.0 ± 3.75
[1.0; 0.15–11.18
2.54 ± 0.57
[2.53; 1.6–3.67]
0.45 ± 0.09
[0.43; 0.37–0.68]
0.85 ± 0.07
[0.86; 0.73–0.94]
0.74 ± 0.11
[0.75; 0.57–0.88]
Mean ± standard deviation [median; minimum–maximum range]
HD Hausdorff distance, MDA mean distance to agreement
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expert prostate MRI readers and the PET-based routine
were equally unsatisfactory. Depending on tumor shape
and the identification of the lesions’ center by human
readers, minimum contour expansions between 11 and
15 mm would have been needed to cover all Gleason ≥ 3+4
disease. Currently applied standard safety margins are typ-
ically 10 mm or less, which our results imply would often
be insufficient.
Ouzzane et al. recently noted that only few studies
with valid methodology attempted to address the crucial
question of safety margins [4]. Depending on the
planned focal treatment method and the lesion location
within the prostate, 4–10 mm safety margins have been
proposed [1, 36, 37]. For example, Ting et al. used irre-
versible electroporation to treat 25 men with low- to
intermediate-risk prostate cancer with a 5-mm mini-
mum safety margin. Short-term follow-up indicated a
24% recurrence rate at 8 months and almost all recur-
rences were adjacent to the treatment zone [2], suggest-
ing that treatment of larger tumor volumes would have
been needed. Safety margins of 4–6 mm near the
sphincter muscle have been advocated to avoid incontin-
ence. Ahmed et al. performed a prospective HIFU trial
involving 56 men with low- (12%), intermediate- (84%),
and high-risk (4%) prostate cancer. Fifty-two men re-
ceived a 6-month post-treatment biopsy, and clinically
significant cancer was found in 10 cases [38]. Other
groups advocate hemiablation to achieve better long-
term disease control with low morbidity [39]. Based on
the available literature, it remains debatable whether
focal prostate cancer treatment is a suitable alternative
to established whole-gland treatment approaches.
While our registration method was designed to
optimize the accuracy of registration between in vivo
MRI and pathology, it is not without error. The quan-
tification of registration errors is difficult because the
processing of human prostate tissues has to follow
established methodological standards. Since the bladder
surface and the prostatic apex are undergoing separate
histological assessments to evaluate for possible extra-
capsular extension of cancer, they are not part of the
final prostate specimen. Fiducial markers could not be
introduced into the specimen after prostatectomy be-
cause they would be dislodged during sectioning of the
whole-mount blocks. Due to the stability constraints of
plastic molds, slits for gross sectioning of the prostate
within the mold were spaced at 3-mm intervals. There-
fore, there was a maximum uncertainty of 3 mm and a
mean uncertainty of 1.5 mm with respect to the pres-
ence or absence of a given lesion on consecutive slices.
Using software interpolation between registered whole-
mount HE slices, as done in this study, will however
lessen uncertainties in tumor border definition. Defor-
mations of the specimen relative to the in vivo geometry
of the prostate are often non-uniform. Bending and
warping energies are particularly high at the lateral per-
ipheral zones of the prostate [22], which increases
registration uncertainties at these locations. While regis-
tration errors of each registration step may add up, it is
unlikely that they are always to the disadvantage of the
Fig. 4 Bubble plot of underestimated tumor volumes. The percentage underestimation of the true tumor volume as determined by histology is
given for the two human readers (seg1, seg2), the gradient-based segmentation method (seg3), and the union of seg1–3 (seg4). The diameter of
the colored bubbles is proportional to the true tumor volume, and the color reflects the patient ID across segmentations (see Table 1). Please
note that the underestimated tumor volume for the patient with the longest time period between imaging and prostatectomy, harboring the
only high-risk cancer in this cohort (patient ID 9), is well within the range of the remaining patients
Piert et al. EJNMMI Research  (2018) 8:23 Page 9 of 14
lesion representation on in vivo T2W MRI used for
tumor segmentation. In fact, when determining the
registration errors of BPH nodules from in vivo over ex
vivo MRI to histology, the HD and MDA of the final
registration (in vivo MRI to histology) increased but was
far less than the sum of the individual registration errors.
Registration errors due to dehydration of internal pros-
tate tissue components during fixation are unavoidable
and will cause shrinkage of the prostate specimen com-
pared to the prostate in the human body [22]. Schned et
al. estimated that the in vivo tumor volume was on aver-
age 12.4% higher than that measured from prostatec-
tomy pathology [40]. Our own measurements obtained
from well-delineated BPH nodules agree with this as-
sessment. The less-than-perfect overlap coefficients
(Dice and Jaccard < 1) obtained from BPH nodules can
Table 4 Inter-reader agreement
Comparison HD (mm) MDA (mm) Dice (range 0–1) Jaccard (range 0–1)
Reader 1 (seg1) vs. reader 2 (seg2) 8.56 ± 4.80
[7.09; 2.84–16.15]
2.43 ± 2.42
[1.46; 0.73–8.42]
0.41 ± 0.19
[0.45; 0.0–0.62]
0.27 ± 0.13
[0.29; 0.0–0.44]
Reader 1 (seg1) vs. 18F-choline PETEdge (seg3) 8.25 ± 3.95
[8.30; 4.37–14.27]
2.47 ± 1.43
[2.08; 1.07–4.60]
0.37 ± 0.14
[.0.41; 0.11–0.50]
0.23 ± 0.10
[0.26; 0.06–0.34]
Reader 2 (seg2) vs. 18F-choline PETEdge (seg3) 9.73 ± 5.22
[8.72; 3.09–18.16]
2.97 ± 1.91
[2.11; 0.90–7.12]
0.32 ± 0.14
[0.27; 0.15–0.54]
0.20 ± 0.10
[0.16; 0.08–0.37]
Mean ± standard deviation [median; minimum–maximum range]
HD Hausdorff distance, MDA mean distance to agreement
Fig. 5 Tumor segmentation results. Registered transaxial 18F-choline PET (a), ADC (b), T2W MRI (c), and 18F-choline fusion PET/MRI (d) are shown
(SUV range 0–15). Contours of a Gleason 3+4 prostate cancer are displayed on corresponding slices obtained from registered histology (blue line
and contour shadow) and compared to registrations from two human readers (red and green line and a contour obtained from 8F-choline PET
(yellow)) using a semiautomatic thresholding method (e–h). A contour combining these three segmentations with an added safety margin of
5 mm (lime line) completely covers the histological tumor volume
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therefore in part be attributed to fixation-induced BPH
shrinkage. Conversely, tumor shrinkage may have been
smaller than in normal glandular tissue due to higher
cellularity of tumors. Nonetheless, tumor shrinkage bears
the potential to further underestimate tumor volumes on
imaging relative to pathology.
As recently reviewed, the data on tumor volume esti-
mates by MRI relative to histology are mixed; however,
most published data report an underestimation of tumor
volumes by mpMRI [32]. What may appear surprising in
our study is the extent of the underestimation compared
to prior reports. When considering the technical im-
provements of mpMRI over the last decade with the
availability of 3 T MRI, one would expect improving ac-
curacy in tumor border delineation. However, consider-
ing three prior reports comparing mpMRI at 3 T with
whole-mount histology [27, 41, 42], two of which used
3D molds for sectioning, underestimation of tumor vol-
umes between 7 and 80% were noted. The lowest under-
estimation was found by Turkbey et al. [27]; however,
their study was limited due to tumor volume measure-
ments based on an ellipsoid formula rather than a true
volumetric measurement, which based on our data
significantly overestimates lesion volumes. Also, gross
sectioning of prostate specimen was performed manually
in almost half of the subjects, which is technically ex-
tremely difficult to be done at 4-mm intervals thereby
introducing errors [22]. Furthermore, they did not ac-
count for misplacement of tumor borders on histology
relative to in vivo MRI as done in our study. Le Nobin
et al. did not use 3D molds to facilitate registration of
MRI and histology, nonetheless reporting on average
57% greater tumor volumes on histology vs. mpMRI
evaluating retrospectively 46 lesions of overall smaller
volume (mean 1.1 mL) compared to our cohort [42].
More recently, Priester et al. studied 114 subjects
undergoing prostatectomy using individually 3D-printed
molds for sectioning. The mean volume (2.5 mL) of 107
clinically significant prostate cancers was similar to our
data, and the majority of tumors were graded as
Gleason ≥ 3+4 [41]. Although they did not determine
volumetric similarity coefficients, their overall results are
comparable to our study. Eighty percent of the cancer vol-
ume from matched tumors was outside of the MR-defined
tumor volume, a result that is very similar compared to
our own data. The mean HD between histology and
mpMRI of clinically significant tumors was 15.6 mm,
which was even worse compared to our data (HD of
9.3–10.7 mm for human readers).
A potential reason for the observed disparities of
tumor volume estimates obtained from in vivo imaging
vs. histology from prostatectomy specimen could have
been related to interim tumor growth, particularly as 5
of 10 patients underwent surgery roughly 5–7 months
after imaging. While absolute volume growth rates of
untreated Gleason ≥ 3+4 cancers are unknown, adeno-
carcinomas of the prostate are typically progressing
slowly [43]. Supporting evidence for slow progression of
intermediate risk prostate cancer comes from the obser-
vation arms of the Scandinavian Prostate Cancer Group
Study Number 4 [44] and the Protect trial [45]. Indeed,
9 of 10 patients included in our cohort harbored
intermediate-risk (Gleason 3+4 or 4 + 3) cancer. In one
patient with high-risk cancer (Gleason 4+5) and the
longest time interval (204 days) between imaging and
prostatectomy (patient 9 in Table 1 and Fig. 4), the
underestimated tumor volume was however well within
the range of other segmentations. Therefore, we con-
sider interval tumor growth not to be a significant con-
tributing factor for the observed underestimation of the
tumor volumes.
While the underestimation of tumor volumes on PET
can be attributed to technical aspects of PET imaging in-
cluding partial volume effects limiting image resolution
[46], the reasons for underestimated tumor volumes on
MRI are less clear. One possibility could be an inhomo-
geneity of Gleason pattern within a given tumor, where
the “detectable” center of such lesions has higher cellular
density compared to the periphery of lesions. Since
Gleason 3+3 cancers are often missed on MRI [41] and
lack focal elevated 11C-choline [46] and 18F-choline
uptake on PET above background [21], we investigated
whether mpMRI may only have identified certain pockets
of more aggressive disease (Gleason ≥ 3+4), while missing
areas of low-grade disease within inhomogeneous prostate
cancers. However, a specific analysis of all Gleason ≥ 3+4
cancers did not identify any inhomogeneity of Gleason
pattern within individual lesions that could explain the
profound underestimation of tumor volumes. Nonethe-
less, missed tumors are often small and have lower grade
than visible tumors on MRI. In addition, non-visible dis-
ease may display benign prostatic glandular tissue inter-
mixed with carcinoma [47]. Not only the cellular density
or its distribution, but also the cellular composition, par-
ticularly the amount of interstitial stromal space, has an
effect on DWI and derived ADC maps [48]. Since DWI
plays an important role for visual identification of prostate
cancer on mpMRI, this phenomenon could explain—at
least in part—the underestimation of tumor volumes and
underlying uncertainties about tumor borders.
Conclusions
Visual tumor segmentation based by mpMRI and semi-
automatic segmentation based on 18F-choline uptake
measures significantly underestimated the true volume
of Gleason ≥ 3+4 prostate cancer, and substantial safety
margins (up to 15 mm in our series) are required to
include all diseases. Combining MR-based human
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segmentations with a semi-automated thresholding
approach based on 18F-choline PET reduced the
necessary safety margin to a maximum of 9 mm. While
further work in a larger cohort is needed to validate
these findings, this approach might contribute to
improving the outcome of focal therapies of significant
prostate cancer.
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